Opthea to Present at Oppenheimer Healthcare Conference
Opthea (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases including wet age-related macular degeneration (wet AMD), has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
The company's Chief Executive Officer, Frederic Guerard, PharmD, will deliver a presentation on Tuesday, February 11, 2025, at 10:00 AM ET and will be available for one-on-one meetings during the conference, which runs from February 11-12, 2025. The presentation will be accessible via webcast and will also be available on the company's investor relations website.
Opthea (ASX/NASDAQ:OPT), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie innovative per le malattie retinali, tra cui la degenerazione maculare legata all'età umida (wet AMD), ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Vita di Oppenheimer.
Il CEO dell'azienda, Frederic Guerard, PharmD, presenterà un intervento martedì 11 febbraio 2025, alle 10:00 AM ET e sarà disponibile per incontri individuali durante la conferenza, che si svolgerà dall'11 al 12 febbraio 2025. La presentazione sarà accessibile via webcast e sarà disponibile anche sul sito web delle relazioni con gli investitori dell'azienda.
Opthea (ASX/NASDAQ:OPT), una compañía biofarmacéutica en etapa clínica centrada en desarrollar terapias novedosas para enfermedades retinianas, incluyendo la degeneración macular asociada a la edad húmeda (wet AMD), ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Vida de Oppenheimer.
El Director Ejecutivo de la empresa, Frederic Guerard, PharmD, realizará una presentación el martes 11 de febrero de 2025, a las 10:00 AM ET y estará disponible para reuniones individuales durante la conferencia, que se llevará a cabo del 11 al 12 de febrero de 2025. La presentación será accesible a través de un webcast y también estará disponible en el sitio web de relaciones con inversores de la compañía.
Opthea (ASX/NASDAQ:OPT), 망막 질환, 특히 습성 노인성 황반변성(wet AMD)에 대한 혁신적인 치료제를 개발하는 임상 단계의 생명 공학 회사가 Oppenheimer 제35회 연례 생명 과학 컨퍼런스에 참여한다고 발표했습니다.
회사의 CEO인 Frederic Guerard, PharmD는 2025년 2월 11일 화요일, 동부표준시 10:00 AM에 발표를 진행하며, 2025년 2월 11일부터 12일까지 열리는 컨퍼런스 동안 일대일 미팅을 위해 참석할 예정입니다. 발표는 웹캐스트를 통해 접근할 수 있으며 회사의 투자자 관계 웹사이트에서도 확인할 수 있습니다.
Opthea (ASX/NASDAQ:OPT), une entreprise biopharmaceutique en phase clinique spécialisée dans le développement de thérapies novatrices pour les maladies rétiniennes, y compris la dégénérescence maculaire liée à l'âge humide (wet AMD), a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Vie d'Oppenheimer.
Le PDG de l'entreprise, Frederic Guerard, PharmD, fera une présentation le mardi 11 février 2025, à 10h00 ET et sera disponible pour des réunions individuelles pendant la conférence, qui se déroulera du 11 au 12 février 2025. La présentation sera accessible via webdiffusion et sera également disponible sur le site web des relations avec les investisseurs de l'entreprise.
Opthea (ASX/NASDAQ:OPT), ein biopharmazeutisches Unternehmen in klinischer Entwicklung, das sich auf die Entwicklung neuartiger Therapien für Netzhauterkrankungen, einschließlich feuchter altersbedingter Makuladegeneration (wet AMD), konzentriert, hat seine Teilnahme an der 35. Jahrestagung der Healthcare Life Sciences Conference von Oppenheimer angekündigt.
Der CEO des Unternehmens, Frederic Guerard, PharmD, wird am Dienstag, den 11. Februar 2025, um 10:00 Uhr ET eine Präsentation halten und steht während der Konferenz, die vom 11. bis 12. Februar 2025 stattfindet, für Einzelgespräche zur Verfügung. Die Präsentation wird über einen Webcast zugänglich sein und auch auf der Website der Investor Relations des Unternehmens verfügbar sein.
- None.
- None.
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings.
Details are as follows:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | |
| Date: | February 11-12, 2025 |
| Presentation: | Tuesday, February 11, 2025, 10:00 AM ET |
| Webcast Link: | https://wsw.com/webcast/oppenheimer39/opt/2588856 |
| The webcast will also be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/. | |
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic macular edema (DME), which remain leading causes of vision loss worldwide.
Opthea’s lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. Sozinibercept has the potential to become the first therapy in 20 years to enable patients with wet AMD live fuller and healthier lives.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
| Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email:pkelleher@lifesciadvisors.com Phone: 617-430-7579 | Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email:silvana@nsgpllc.com |
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When is Opthea (OPT) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Opthea's (OPT) Oppenheimer conference presentation?
What is the main focus of Opthea's (OPT) drug development program?
Will Opthea (OPT) offer one-on-one meetings during the Oppenheimer conference?
